NOT FDA-APPROVED · MULTIPLE SAFETY CONCERNS

Melanotan II

A synthetic melanocortin agonist sold online as an unregulated tanning peptide. Public health agencies in multiple countries have warned consumers against it. We cover it because it's widely searched, not because the use case is supported.

Important: Melanotan II carries documented safety concerns

Public health agencies including the UK Medicines and Healthcare products Regulatory Agency (MHRA), Australia's Therapeutic Goods Administration (TGA), and the U.S. Food and Drug Administration have issued consumer warnings against Melanotan II products. Reported adverse events include priapism (prolonged painful erection requiring emergency care), severe nausea, blood-pressure changes, and case reports of melanoma occurring in users. The compound has not gone through the clinical-development process that would establish a safe-use profile.

This page exists for educational completeness. Anyone considering Melanotan II should be aware that it operates entirely outside any regulatory framework, that the products sold online are not quality-controlled, and that the safety literature is meaningfully concerning. If you have any of the conditions discussed on this page, talk to a licensed clinician.

The 30-second read

Melanotan II is a synthetic peptide that activates melanocortin receptors, especially MC1R (which controls skin pigmentation) and MC4R (which affects appetite and sexual response). It produces tanning without UV exposure and was originally developed as a research compound at the University of Arizona in the 1980s. It was never approved as a drug. The compound is sold online in unregulated channels for tanning, and is also informally used for sexual-response effects (which led to the development of bremelanotide / PT-141, the FDA-approved descendant). The safety record is concerning: documented reports of priapism, nausea, blood-pressure spikes, melanoma cases in users, and the compounded products themselves vary in identity and purity.

Why this is on people's radar

Melanotan II has been in informal use for nearly twenty years. The original research at the University of Arizona explored it as a potential treatment for skin conditions and as a way to induce protective tanning in fair-skinned people at high skin-cancer risk. Clinical development for those medical applications was abandoned, but the compound, easy to synthesize and easy to use, moved into informal "research peptide" channels and online tanning-product markets.

The cultural footprint expanded beyond tanning when users noticed prominent sexual-response effects (libido and erection). That observation led to clinical development of a related compound, bremelanotide (PT-141), which was eventually FDA-approved in 2019 for hypoactive sexual desire disorder in premenopausal women. Bremelanotide is the regulated, approved descendant of the Melanotan II line of research; Melanotan II itself never went through that process.

Public-health agencies in the UK, Australia, Norway, and other countries have repeatedly warned consumers against Melanotan II products, citing safety concerns and the unregulated nature of the supply. The FDA in the U.S. has also issued warnings. Despite this, the compound has remained in informal use, and is what most readers are searching for when they look up "melanotan."

A note on framing this page

For most peptides on this site, we have a "what people are usually trying to do with it" section, three or four plain-language goals readers might recognize. We're handling Melanotan II differently. The implied use cases (tanning without sun, sexual-response effects) are not supported by clinical-grade evidence, and framing them as plausible goals would understate how unsettled the safety picture is.

What we will say: people search for this compound for tanning effects and for sexual-response effects. Both have been documented in users. Neither has been studied in a clinical-trial framework that would establish a safe-use profile, and both come with documented adverse events. The clinical development that did continue, bremelanotide / PT-141 for sexual desire, is the regulated path forward in this corner of pharmacology.

What the science actually shows

Plain-English summary of the literature:

Tanning effects are real, mechanism is established

Melanotan II activates MC1R on melanocytes, stimulating melanin production. Skin darkening following injection has been reported consistently in users and in early clinical work. The mechanism is well understood.1

Sexual-response effects led to a different drug

The libido and erection effects reported in early Melanotan II work led to clinical development of bremelanotide (PT-141), which was FDA-approved in 2019 (Vyleesi) for premenopausal HSDD. Bremelanotide is the regulated, studied successor to this line of compounds.2

Priapism is a documented adverse event

Multiple case reports describe priapism (sustained painful erection requiring emergency intervention) in Melanotan II users. This is a recognized risk of melanocortin-receptor agonism in this dose range.3

Melanoma case reports are concerning

The medical literature contains case reports of new melanomas and changing nevi in Melanotan II users. Whether the compound is causally linked to these events or selecting for a population already at higher risk hasn't been definitively established, but the case-report signal exists.4

Other adverse events are common

Nausea, flushing, blood-pressure fluctuations, GI upset, spontaneous erections, and changes in appetite are reported regularly. Severe reactions including kidney injury and rhabdomyolysis have been reported in case literature.5

Product identity and purity are not regulated

Products sold as Melanotan II in online channels are not subject to identity or purity testing. Several published analyses of online-sourced products have found variable peptide content, contaminants, or different compounds entirely.6

The honest read

What's solid:

The mechanism of Melanotan II at melanocortin receptors is well characterized. Tanning effects in users are real. The line of research did produce a legitimate, FDA-approved drug, bremelanotide / PT-141, for sexual desire disorder.

What's still being worked out:

Whether the melanoma case reports reflect a causal relationship with the compound or selection of an already at-risk population. Whether long-term use carries cumulative risks beyond what acute case reports suggest. The absence of clinical-grade trials means many basic safety questions remain unanswered.

What's hyped beyond the evidence:

The framing of Melanotan II as a "safe sunless tan." The compound has not gone through the clinical-development pathway that would establish that profile, agencies in multiple countries have warned against it, and the documented adverse-event list is meaningfully concerning. The regulated successor compound for the sexual-response use case (bremelanotide) exists and went through FDA review for a reason.

Things to know if you're researching this compound

  • Public-health warnings exist: the UK MHRA, Australia TGA, Norwegian Medicines Agency, and FDA have all issued warnings against Melanotan II products.
  • Distinct from Melanotan I: Melanotan I (afamelanotide / Scenesse) is FDA-approved for the rare condition erythropoietic protoporphyria. Melanotan II is a different molecule and is not approved.
  • Distinct from PT-141 / bremelanotide: Bremelanotide (Vyleesi) is the FDA-approved descendant peptide for sexual desire disorder in premenopausal women. It is the regulated path forward in this molecular family.
  • Priapism is a recognized risk: sustained erection beyond a few hours is a urological emergency. This adverse event is documented in users.
  • Melanoma surveillance: any new or changing pigmented skin lesion warrants prompt dermatology evaluation. Users should be especially cautious here.
  • Product identity is uncontrolled: what's actually in vials sold as Melanotan II varies. Independent analyses have found inconsistent content.
  • Mechanism, dosing, and references: in the "Want to go deeper?" section below.

What people often ask

What's the difference between Melanotan I and Melanotan II?

They're different molecules with different receptor selectivity. Melanotan I (afamelanotide / Scenesse) is FDA-approved for erythropoietic protoporphyria, a rare light-sensitivity disorder. Melanotan II is structurally different, not FDA-approved, and has a broader receptor activation profile that drives the sexual-response and adverse-event side. Melanotan II is what most people mean when they search for "melanotan."

Is it the same thing as PT-141?

No. PT-141 (bremelanotide / Vyleesi) is a related, FDA-approved peptide developed for sexual desire disorder in premenopausal women. It's a separate molecule that went through clinical development. PT-141 has its own page on this site.

Is Melanotan II legal?

It's not FDA-approved as a drug. Selling it for human use is illegal in many countries. It's often sold online with disclaimers calling it "research-only" or "not for human consumption", these labels are how vendors operate in legal grey zones, but they don't make the products safer or more regulated.

Does it actually cause melanoma?

The medical literature contains case reports of melanoma and changing pigmented lesions in Melanotan II users. Whether the relationship is causal or whether users are a population already at higher melanoma risk hasn't been definitively established. The case-report signal is there and is taken seriously by dermatologists.

Why is this page on the site if you're warning people away from it?

Because people search for it, and a "peptides explained honestly" site that pretends Melanotan II doesn't exist isn't being honest. The right answer to the question "what is this?" is "here's what it is and here's why public-health agencies are concerned about it", not silence.

FDA and regulatory status

Status as of May 5, 2026: Melanotan II is not FDA-approved for any indication. The FDA, the UK MHRA, Australia's TGA, and other national agencies have issued consumer warnings against Melanotan II products. The related compound bremelanotide (Vyleesi / PT-141) is FDA-approved for hypoactive sexual desire disorder in premenopausal women. The other related compound afamelanotide (Scenesse / Melanotan I) is FDA-approved for erythropoietic protoporphyria. Status updates land here when they happen.

Want to go deeper? Mechanism, the melanocortin receptor system, and references.

Background

Melanotan II is a cyclic heptapeptide synthetic analog of α-melanocyte-stimulating hormone (α-MSH). It was developed at the University of Arizona in the 1980s under the direction of Mac Hadley and Victor Hruby as part of a research program exploring melanocortin-receptor agonists as protective tanning agents and treatments for sexual dysfunction. The compound has the structure Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2.

Mechanism of action

Melanotan II is a non-selective agonist at melanocortin receptors. Its primary clinical-relevant activities are at MC1R (peripheral, on melanocytes, drives melanin production) and MC4R (central, in hypothalamus, drives appetite suppression and sexual response). It also has activity at MC3R and MC5R. The non-selective profile is a key reason adverse events span tanning, GI, sexual-response, and cardiovascular domains. The FDA-approved descendant compound bremelanotide retains MC4R activity for the sexual-desire indication while having a different overall pharmacologic profile.

Adverse-event profile in the literature

The published literature on Melanotan II adverse events includes priapism case reports, dermatologic concerns including new melanomas and changing nevi in users, GI symptoms (severe nausea common), blood-pressure fluctuations, spontaneous yawning and stretching reactions, kidney injury including rhabdomyolysis, and renal failure case reports. Product-quality literature documents inconsistent identity and purity in online-sourced products.

Dosing context

This site does not provide dosing protocols for unregulated compounds with documented safety concerns. Published academic-research dosing existed in the original University of Arizona work, but that work was discontinued and the compound was never approved for human use. Anyone with questions about the compound should consult a licensed clinician.

References

  1. Dorr RT, et al. (1996). "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sci, 58(20), 1777–1784. PubMed
  2. Kingsberg SA, et al. (2019). "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." Obstet Gynecol, 134(5), 899–908. PubMed
  3. Brennan R, et al. (2008). "Use of melanotan I and II in the general population." BMJ, 337, a2748. PubMed
  4. Cardones AR, Grichnik JM. (2009). "α-Melanocyte-stimulating hormone-induced eruptive nevi." Arch Dermatol, 145(4), 441–444. PubMed
  5. Habbema L, et al. (2017). "Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review." Int J Dermatol, 56(10), 975–980. PubMed
  6. Breindahl T, et al. (2015). "Identification of synthetic peptides in counterfeit drug products." Various analytical-chemistry case reports of online-sourced products. PubMed
  7. U.S. Food and Drug Administration. "Tanning Pills." Consumer health information. FDA.gov
  8. UK Medicines and Healthcare products Regulatory Agency. "Melanotan products: warnings to consumers." MHRA
For educational and research purposes only. This is not medical advice. Melanotan II is not FDA-approved and has documented safety concerns including priapism, melanoma case reports, and adverse events affecting multiple organ systems. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.